ECRU Translational Research Division (TRD), under the direction of Dr Anthony Dear, is the development arm of ECRU which conducts a number of translational research projects in multiple disciplines. ECRU Biotech maintains their laboratories at the Alfred Hospital.
Currently ECRU TRD is involved in the evaluation of compounds, in vitro and in vivo, currently used clinically in the treatment of diabetes with a view to determining their potential for vascular protection. In addition ECRU TRD has established, with its collaborators, several in vivo systems for assessment of novel and existing agents in the setting of disease states ranging from metastatic cancer to vascular disease. ECRU TRD is supported by Monash University, individual principal investigators from ECRU’s clinical operations, has strong links with the pharmaceutical industry, and is engaged in seeking funding from both the public and private sectors in order to further its research activities. ECRU TRD also seeks to provide an environment for ongoing academic endeavours, including postgraduate studies, with biotechnology research projects for B.Sc (Hons) and PhD students being available.
Dr Dear’s research interests include vascular medicine, haematology, and pharmacogenetic testing and he holds an appointment at The Eastern Health Clinical School and The Australian Centre for Blood Diseases (ACBD), Monash University AMREP facility where he heads the Eastern Clinical Research Unit (ECRU) Translational Research Division Laboratory.
Dr Dear is involved in several scientific collaborations with national and international research groups, and is co-investigator in numerous International clinical trials. He is a member of the editorial board of the journal Oncology Letters and is also a member of the Australian Society of Thrombosis and Haemostasis (ASTH) and the Australian Vascular Biology Society (AVBS).
Dr Anthony Dear
Telephone: +61 3 9091 8873
Fax: +61 3 9899 6810